Modernizing Opioid Treatment Access Act 2.0 of 2026
- Sponsor
- Sen. Markey, Edward J. [D-MA]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jun 24, 2026
Bottom line
The bill aims to broaden methadone access for opioid use disorder by enabling pharmacy dispensing and telemedicine, while including safeguards and state flexibility.
What it actually does
This bill significantly expands access to methadone for opioid use disorder (OUD) by allowing specially qualified practitioners to prescribe it for dispensing through pharmacies, moving beyond the traditional Opioid Treatment Program (OTP) model. It mandates electronic prescribing, permits telemedicine for treatment, requires specific informed consent regarding confidentiality, and allows states to opt out of the new framework. The bill also requires annual reporting from the DEA on its implementation.
Proponents argue
Supporters argue this bill will drastically reduce barriers to accessing life-saving methadone treatment, especially for individuals in rural areas or those facing logistical challenges with daily OTP visits. They emphasize that expanding access through pharmacies, with appropriate safeguards and telemedicine options, can help address the ongoing opioid crisis by making treatment more patient-centered and convenient, ultimately saving lives and improving public health outcomes.
Opponents contend
Critics might raise concerns about the potential for increased diversion of methadone if dispensed through pharmacies, arguing that the current OTP model provides a more controlled environment with comprehensive support services. They may also question the adequacy of safeguards, particularly regarding informed consent and the qualifications of practitioners, and express worries about the impact on the existing OTP infrastructure and the potential for reduced engagement with holistic care.
The bill is very short and straightforward, allowing ample time for a thorough review and understanding of its provisions and implications.
Section 2, amending 21 U.S.C. 823(h)(2)(A)
Waiver of OTP Requirements for Methadone Prescribing
This provision waives the existing requirement that methadone for opioid use disorder (OUD) must be dispensed only through highly regulated Opioid Treatment Programs (OTPs). Instead, it creates a new pathway for qualified practitioners to prescribe methadone, allowing it to be dispensed by pharmacies. This fundamentally shifts how methadone treatment can be accessed, moving away from the traditional clinic-based model for certain patients.
Supporters argue
Proponents argue this waiver is crucial for modernizing OUD treatment, making it more accessible and integrated into mainstream healthcare, thereby reducing stigma and improving patient outcomes, especially in underserved areas.
Critics contend
Opponents may argue that the current OTP model, with its comprehensive services and strict oversight, is essential for patient safety and preventing diversion, and that this waiver could compromise those safeguards.
Tradeoffs
This provision balances increased access and patient convenience against potential risks of diversion and the need for comprehensive support services traditionally offered by OTPs.
Section 2, amending 21 U.S.C. 823(h)(2)(B)
Establishment of Qualified Practitioner Registration for Methadone Prescribing
This section defines who can prescribe methadone for OUD under the new pharmacy-dispensing model. It limits this authority to physicians and psychiatrists with specific board certifications in addiction medicine or addiction psychiatry, or other practitioners deemed qualified by the Secretary of Health and Human Services. This ensures that only healthcare professionals with specialized expertise can utilize this expanded prescribing power.
Section 2, amending 21 U.S.C. 823(h)(2)(C) and (H)
Prescribing and Dispensing Requirements
This provision mandates that methadone prescriptions under this new model must be exclusively electronic, comply with existing federal and state quantity limits, and be for liquid or dispersible tablet formulations. It also clarifies that pharmacies dispensing these prescriptions do not need a separate DEA registration. These rules aim to ensure secure prescribing, prevent over-dispensing, and facilitate pharmacy involvement without undue regulatory burden.
Section 2, amending 21 U.S.C. 823(h)(2)(D) and (E)
Continued Access to OTP Care and Informed Consent
This section clarifies that individuals receiving methadone through pharmacies under this new model must still have access to other care provided by an Opioid Treatment Program (OTP). It also requires practitioners to obtain specific informed consent from patients, detailing the differences in confidentiality protections when methadone is dispensed through a pharmacy versus an OTP. This ensures patients understand their treatment options and privacy implications.
Section 2, amending 21 U.S.C. 823(h)(2)(F) and (G)
State Opt-Out and Telemedicine Provisions
This provision grants states the authority to opt out of the new methadone prescribing model. If a state requests it, the Attorney General must cease registering new practitioners, revoke existing registrations, and deny pending applications within that state. Additionally, it explicitly permits maintenance or detoxification treatment provided under this new model to be delivered via telemedicine, increasing flexibility for patients in remote areas.
Section 2, amending 21 U.S.C. 823(h)(3)
DEA Reporting Requirements
This section mandates that the Administrator of the Drug Enforcement Administration (DEA) submit annual reports to Congress. These reports must include the number of practitioners registered under the new model in each state, a list of states that opted out, the number of registration revocations or suspensions due to violations, and the number of pharmacies ordering liquid or dispersible tablet methadone. This ensures ongoing oversight and data collection on the implementation and impact of the new policy.
This provision explicitly states that a pharmacy is not required to obtain a separate registration to dispense methadone medication for opioid use disorder when prescribed by a practitioner registered under the new authority.
Section 2, amending 21 U.S.C. 823(h)(2)(H)
Why it matters:This is standard legislative practice to clarify regulatory scope without creating a new, lengthy section for a single exemption. It's a technical detail that significantly impacts implementation by reducing administrative hurdles for pharmacies.
Case for: Supporters argue this exemption is crucial for encouraging pharmacy participation by removing a significant administrative hurdle, thereby facilitating broader access to methadone treatment.
Case against: Critics might argue that requiring a separate registration would provide an additional layer of oversight and accountability for pharmacies handling a high-risk controlled substance, potentially reducing diversion risks.
Estimated impact: Significantly lowers the barrier for pharmacies to dispense methadone, potentially increasing the number of dispensing locations nationwide and improving patient access.
This provision requires practitioners to include in the informed consent process specific information regarding differences in confidentiality protections applicable when methadone is dispensed through an Opioid Treatment Program (OTP) versus a pharmacy.
Section 2, amending 21 U.S.C. 823(h)(2)(E)(ii)
Why it matters:This is a technical detail related to patient privacy, often placed within broader consent requirements. It reflects an awareness of the distinct regulatory environments of OTPs (governed by 42 CFR Part 2) and pharmacies (governed by HIPAA).
Case for: Proponents argue this specific consent is vital for patient autonomy, ensuring individuals understand how their health information might be handled differently when receiving methadone from a pharmacy versus an OTP, where stricter confidentiality rules often apply.
Case against: No strong case against exists, as it is a patient protection measure. Some might argue it adds a layer of complexity to the consent process, but the benefit of informed patient choice generally outweighs this concern.
Estimated impact: Enhances patient privacy protections and ensures transparency regarding data handling, potentially increasing patient trust in the new model and empowering informed decision-making.